History Back
2017 01-19

Grandall Advised China National Medicines in its Reorganization 19 January 2017

On 17 January 2017, the application filed by China National Medicines Corporation Ltd. for purchase of assets by issuing shares was unconditionally passed and approved on the 4th meeting of M&A and Reorganization Committee of CSRC.


The project is recognized as an important approach to the overall reform of Sinopharm Group, covering a large amount of information disclosure and external approval by SASAC, Anti-trust Bureau of MOC and CSRC as well as communication with foreign shareholders.


As the special counsel for the company, Grandall Shanghai Office has rendered professional and overall legal services in the whole process, with WU Xiaoliang, Zhou Yijie, LI Qin, SONG Hongchang, PAN Xiaoxiao, WANG Yin, TAO Yanpei, SHENG Yijie and WU Lin servicing the case.


Global offices: Group Beijing Shanghai Shenzhen Hangzhou Guangzhou Kunming Tianjin Chengdu Ningbo Fuzhou Xi'an Nanjing Nanning Jinan Chongqing Suzhou Changsha Taiyuan Wuhan Guiyang Urumqi Zhengzhou Shijiazhuang Hefei Office Hong Kong Paris Madrid Silicon Valley Stockholm New York
XML 地图 | Sitemap 地图